vs
奥尼兰姆制药（ALNY）与Cloudflare, Inc.（NET）财务数据对比。点击上方公司名可切换其他公司
奥尼兰姆制药的季度营收约是Cloudflare, Inc.的1.9倍（$1.2B vs $614.5M），奥尼兰姆制药净利率更高（17.6% vs -2.0%，领先19.6%），奥尼兰姆制药同比增速更快（96.4% vs 33.6%），过去两年奥尼兰姆制药的营收复合增速更高（33.0% vs 27.4%）
奥尼兰姆制药是美国生物制药企业，2002年成立，总部位于马萨诸塞州剑桥市，专注于研发及商业化针对基因明确疾病的RNA干扰（RNAi）疗法，2016年入选福布斯「100家最具创新力成长企业」榜单。
Cloudflare是总部位于美国加利福尼亚州旧金山的科技企业，提供内容分发网络（CDN）、云网络安全、DDoS防护等多元互联网服务，同时是ICANN认证的域名注册商。其服务作为网站访客与客户托管服务商之间的反向代理，可有效提升访问性能，抵御恶意流量。
ALNY vs NET — 直观对比
营收规模更大
ALNY
是对方的1.9倍
$614.5M
营收增速更快
ALNY
高出62.8%
33.6%
净利率更高
ALNY
高出19.6%
-2.0%
两年增速更快
ALNY
近两年复合增速
27.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $614.5M |
| 净利润 | $206.0M | $-12.1M |
| 毛利率 | 82.2% | 73.6% |
| 营业利润率 | 23.0% | -8.0% |
| 净利率 | 17.6% | -2.0% |
| 营收同比 | 96.4% | 33.6% |
| 净利润同比 | — | 6.0% |
| 每股收益（稀释后） | $1.51 | $-0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALNYNET
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.1B | $614.5M | ||
| Q3 25 | $1.2B | $562.0M | ||
| Q2 25 | $773.7M | $512.3M | ||
| Q1 25 | $594.2M | $479.1M | ||
| Q4 24 | $593.2M | $459.9M | ||
| Q3 24 | $500.9M | $430.1M | ||
| Q2 24 | $659.8M | $401.0M |
净利润ALNYNET
| Q1 26 | $206.0M | — | ||
| Q4 25 | $186.4M | $-12.1M | ||
| Q3 25 | $251.1M | $-1.3M | ||
| Q2 25 | $-66.3M | $-50.4M | ||
| Q1 25 | $-57.5M | $-38.5M | ||
| Q4 24 | $-83.8M | $-12.8M | ||
| Q3 24 | $-111.6M | $-15.3M | ||
| Q2 24 | $-16.9M | $-15.1M |
毛利率ALNYNET
| Q1 26 | 82.2% | — | ||
| Q4 25 | 75.6% | 73.6% | ||
| Q3 25 | 84.2% | 74.0% | ||
| Q2 25 | 81.6% | 74.9% | ||
| Q1 25 | 88.2% | 75.9% | ||
| Q4 24 | 82.7% | 76.4% | ||
| Q3 24 | 83.6% | 77.7% | ||
| Q2 24 | 89.8% | 77.8% |
营业利润率ALNYNET
| Q1 26 | 23.0% | — | ||
| Q4 25 | 12.0% | -8.0% | ||
| Q3 25 | 29.5% | -6.7% | ||
| Q2 25 | -2.1% | -13.1% | ||
| Q1 25 | 3.0% | -11.1% | ||
| Q4 24 | -17.7% | -7.5% | ||
| Q3 24 | -15.4% | -7.2% | ||
| Q2 24 | 7.4% | -8.7% |
净利率ALNYNET
| Q1 26 | 17.6% | — | ||
| Q4 25 | 17.0% | -2.0% | ||
| Q3 25 | 20.1% | -0.2% | ||
| Q2 25 | -8.6% | -9.8% | ||
| Q1 25 | -9.7% | -8.0% | ||
| Q4 24 | -14.1% | -2.8% | ||
| Q3 24 | -22.3% | -3.6% | ||
| Q2 24 | -2.6% | -3.8% |
每股收益（稀释后）ALNYNET
| Q1 26 | $1.51 | — | ||
| Q4 25 | $1.44 | $-0.03 | ||
| Q3 25 | $1.84 | $0.00 | ||
| Q2 25 | $-0.51 | $-0.15 | ||
| Q1 25 | $-0.44 | $-0.11 | ||
| Q4 24 | $-0.66 | $-0.05 | ||
| Q3 24 | $-0.87 | $-0.04 | ||
| Q2 24 | $-0.13 | $-0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7B | $943.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.1B | $1.5B |
| 总资产 | $5.1B | $6.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALNYNET
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.7B | $943.5M | ||
| Q3 25 | $1.5B | $1.1B | ||
| Q2 25 | $1.1B | $1.5B | ||
| Q1 25 | $1.0B | $204.5M | ||
| Q4 24 | $966.4M | $147.7M | ||
| Q3 24 | $1.1B | $182.9M | ||
| Q2 24 | $968.5M | $157.0M |
股东权益ALNYNET
| Q1 26 | $1.1B | — | ||
| Q4 25 | $789.2M | $1.5B | ||
| Q3 25 | $233.9M | $1.3B | ||
| Q2 25 | $250.6M | $1.2B | ||
| Q1 25 | $115.4M | $1.4B | ||
| Q4 24 | $67.1M | $1.0B | ||
| Q3 24 | $32.4M | $973.1M | ||
| Q2 24 | $-3.1M | $881.5M |
总资产ALNYNET
| Q1 26 | $5.1B | — | ||
| Q4 25 | $5.0B | $6.0B | ||
| Q3 25 | $4.9B | $5.8B | ||
| Q2 25 | $4.6B | $5.6B | ||
| Q1 25 | $4.2B | $3.7B | ||
| Q4 24 | $4.2B | $3.3B | ||
| Q3 24 | $4.2B | $3.1B | ||
| Q2 24 | $4.0B | $2.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $190.4M |
| 自由现金流经营现金流 - 资本支出 | — | $105.2M |
| 自由现金流率自由现金流/营收 | — | 17.1% |
| 资本支出强度资本支出/营收 | — | 13.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $287.5M |
8季度趋势，按日历期对齐
经营现金流ALNYNET
| Q1 26 | — | — | ||
| Q4 25 | $163.6M | $190.4M | ||
| Q3 25 | $325.1M | $167.1M | ||
| Q2 25 | $153.7M | $99.8M | ||
| Q1 25 | $-118.3M | $145.8M | ||
| Q4 24 | $-94.7M | $127.3M | ||
| Q3 24 | $43.7M | $104.7M | ||
| Q2 24 | $124.2M | $74.8M |
自由现金流ALNYNET
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $105.2M | ||
| Q3 25 | $313.0M | $82.5M | ||
| Q2 25 | $139.4M | $39.9M | ||
| Q1 25 | $-127.3M | $59.9M | ||
| Q4 24 | $-103.8M | $54.2M | ||
| Q3 24 | $39.5M | $54.5M | ||
| Q2 24 | $116.1M | $45.2M |
自由现金流率ALNYNET
| Q1 26 | — | — | ||
| Q4 25 | 12.8% | 17.1% | ||
| Q3 25 | 25.1% | 14.7% | ||
| Q2 25 | 18.0% | 7.8% | ||
| Q1 25 | -21.4% | 12.5% | ||
| Q4 24 | -17.5% | 11.8% | ||
| Q3 24 | 7.9% | 12.7% | ||
| Q2 24 | 17.6% | 11.3% |
资本支出强度ALNYNET
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 13.9% | ||
| Q3 25 | 1.0% | 15.1% | ||
| Q2 25 | 1.8% | 11.7% | ||
| Q1 25 | 1.5% | 17.9% | ||
| Q4 24 | 1.5% | 15.9% | ||
| Q3 24 | 0.8% | 11.7% | ||
| Q2 24 | 1.2% | 7.4% |
现金转化率ALNYNET
| Q1 26 | — | — | ||
| Q4 25 | 0.88× | — | ||
| Q3 25 | 1.29× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALNY
| AMVUTTRA | $889.9M | 76% |
| GIVLAARI | $74.4M | 6% |
| OXLUMO | $51.3M | 4% |
| Royalty revenue | $49.0M | 4% |
| Regeneron Pharmaceuticals | $46.3M | 4% |
| Roche | $35.6M | 3% |
| ONPATTRO | $20.5M | 2% |
NET
| Sales Channel Directly To Consumer | $438.5M | 71% |
| Sales Channel Through Intermediary | $176.0M | 29% |
